CHEO Research Institute Logo
Decrease Text SizeIncrease Text SizeFacebookTwitterYoutube

researchers working in a lab

Pranesh Chakraborty photo of Pranesh Chakraborty
Investigator, CHEO Research Institute
Director, Newborn Screening Ontario
Physician, Section of Metabolism and Newborn Screening,
Department of Pediatrics, CHEO
Medical Director, BORN Ontario
Associate Professor, Department of Pediatrics, Faculty of Medicine,
University of Ottawa (cross appointed to Department of BMI and to Pathology and Laboratory Medicine)
613-737-7600 Ext. 3437
Research Practice Areas:
Current Research:
Dr. Chakraborty has three current areas of research interest:
  1. Development and evaluation of novel laboratory assays for diagnosis and screening of inborn errors of metabolism.
  2. Clinical and health services research on outcomes of children with inborn errors of metabolism.
  3. Basic translation research on inborn errors of mitochondrial tRNA metabolism.
Research Team:
  • Larry Fisher
  • Hapsatou Mamady
  • Nathan McIntosh
  • Mylene Theriault
Dr. Chakraborty is a physician certified by the Royal College in Medical Biochemistry and Pediatrics, with a subspecialty in Biochemical Genetics. He joined CHEO in 2003 as a clinician seeing patients with Inborn Errors of Metabolism (IEM). In 2006 he led the transition of Ontario’s newborn screening program to Ottawa leading to the establishment of Newborn Screening Ontario (NSO) at CHEO. In 2008 he was instrumental in the founding of the Better Outcomes Registry and Network (BORN Ontario) at CHEO as a prescribed registry in Ontario. Finally, he is a Principal Investigator for the Canadian Inherited Metabolic Disease Research Network which recently was awarded a $1.5M CIHR Emerging Teams grant for rare disease research. Throughout his career, he has been involved in clinical and translational research related to IEM.
Sample Publications:
Etchegary H, Nicholls SG, Tessier L, Simmonds C, Potter BK, Brehaut JC, Pullman D, Hayeems R, Zelenietz S, Lamoureux M, Milburn J, Turner L, Chakraborty P, Wilson B. Consent for newborn screening: parents' and health-care professionals' experiences of consent in practice. Eur J Hum Genet 2016; 24(11):1530-1534.

Grams SE, Argiropoulos B, Lines M, Chakraborty P, Gowan-Jordan J, Geraghty MT, Tsang M, Eswara M, Tezcan K, Adams KL, Linck L, Himes P, Kostiner D, Zand DJ, Stalker H, Driscoll DJ, Huang T, Rosenfeld JA, Li X, Chen E. Genotype-phenotype characterization in 13 individuals with chromosome Xp11.22 duplications. Am J Med Genet A 2016; 170A(4):967-977.
Karaceper MD, Chakraborty P, Coyle D, Wilson K, Kronick JB, Hawken S, Davies C, Brownell M, Dodds L, Feigenbaum A, Fell DB, Grosse SD, Guttmann A, Laberge AM, Mhanni A, Miller FA, Mitchell JJ, Nakhla M, Prasad C, Rockman-Greenberg C, Sparkes R, Wilson BJ, Potter BK. The health system impact of false positive newborn screening results for medium-chain acyl-CoA dehydrogenase deficiency: a cohort study. Orphanet J Rare Dis 2016; 11:12.

Daoud H, Luco SM, Li R, Bareke E, Beaulieu C, Jarinova O, Carson N, Nikkel SM, Graham GE, Richer J, Armour C, Bulman DE, Chakraborty P, Geraghty M, Lines MA, Lacaze-Masmonteil T, Majewski J, Boycott KM, Dyment DA. Next-generation sequencing for diagnosis of rare diseases in the neonatal intensive care unit. CMAJ 2016; 188(11):E254-E260.

Hayeems RZ, Miller FA, Barg CJ, Bombard Y, Kerr E, Tam K, Carroll JC, Potter BK, Chakraborty P, Davies C, Milburn J, Patton S, Bytautas JP, Taylor L, Price A, Gonska T, Keenan K, Ratjen F, Guttmann A. Parent Experience With False-Positive Newborn Screening Results for Cystic Fibrosis. Pediatrics 2016; 138(3).

Hayeems RZ, Miller FA, Barg CJ, Bombard Y, Cressman C, Painter-Main M, Wilson B, Little J, Allanson J, Avard D, Giguere Y, Chakraborty P, Carroll JC. Using Newborn Screening Bloodspots for Research: Public Preferences for Policy Options. Pediatrics 2016; 137(6).

Khangura SD, Tingley K, Chakraborty P, Coyle D, Kronick JB, Laberge AM, Little J, Miller FA, Mitchell JJ, Prasad C, Siddiq S, Siriwardena K, Sparkes R, Speechley KN, Stockler S, Trakadis Y, Wilson BJ, Wilson K, Potter BK. Child and family experiences with inborn errors of metabolism: a qualitative interview study with representatives of patient groups. J Inherit Metab Dis 2016; 39(1):139-147.

Liwak-Muir U, Dobson CC, Naing T, Wylie Q, Chehade L, Baird SD, Chakraborty PK, Holcik M. ERK8 is a novel HuR kinase that regulates tumour suppressor PDCD4 through a miR-21 dependent mechanism. Oncotarget 2016; 7(2):1439-1450.

Liwak-Muir U, Mamady H, Naas T, Wylie Q, McBride S, Lines M, Michaud J, Baird SD, Chakraborty PK, Holcik M. Impaired activity of CCA-adding enzyme TRNT1 impacts OXPHOS complexes and cellular respiration in SIFD patient-derived fibroblasts. Orphanet J Rare Dis 2016; 11(1):79.

Potter BK, Khangura SD, Tingley K, Chakraborty P, Little J. Translating rare-disease therapies into improved care for patients and families: what are the right outcomes, designs, and engagement approaches in health-systems research? Genet Med 2016; 18(2):117-123.

Saleh DS, Lawrence S, Geraghty MT, Gallego PH, McAssey K, Wherrett DK, Chakraborty P. Prediction of congenital hypothyroidism based on initial screening thyroid-stimulating-hormone. BMC Pediatr 2016; 16:24.

Siddiq S, Wilson BJ, Graham ID, Lamoureux M, Khangura SD, Tingley K, Tessier L, Chakraborty P, Coyle D, Dyack S, Gillis J, Greenberg C, Hayeems RZ, Jain-Ghai S, Kronick JB, Laberge AM, Little J, Mitchell JJ, Prasad C, Siriwardena K, Sparkes R, Speechley KN, Stockler S, Trakadis Y, Wafa S, Walia J, Wilson K, Yuskiv N, Potter BK. Experiences of caregivers of children with inherited metabolic diseases: a qualitative study. Orphanet J Rare Dis 2016; 11(1):168.
Take Action
Quick Links

Our Researchmagnifying glass

abcefg hijklmnopqrst uvwxyz